Patents Examined by Phyllis G. Spivack
  • Protective role of semapimod in necrotizing enterocolitis
    Patent number: 7795314
    Abstract: A method is described wherein semapimod is administered, or a salt thereof, or a combination of semapimod and a salt thereof, for the treatment of necrotizing enterocolitis.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: September 14, 2010
    Assignee: Cytokine PharmaSciences, Inc.
    Inventors: Ruben Zamora, Henri R. Ford, Thais Sielecki-Dzurdz, Vidal F. De La Cruz
  • Method of treating hepatic disease using Aadenosine receptor antagonists
    Patent number: 7795268
    Abstract: The invention is related to methods of treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: September 14, 2010
    Assignee: Gilead Palo Alto, Inc.
    Inventors: Dewan Zeng, Hongyan Zhong, Luiz Belardinelli
  • Phenoxyalkycarboxylic acid derivatives in the treatment of ulcerative colitis
    Patent number: 7786169
    Abstract: A method of treating ulcerative colitis in a patient suffering therefrom comprising: administering an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or esters thereof:
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: August 31, 2010
    Assignee: MediciNova, Inc.
    Inventors: Kenneth Walter Locke, Charles G. Smith, Takashi Kiyoizumi
  • Use of neurokinin antagonists in the treatment of urinary incontinence
    Patent number: 7776851
    Abstract: This invention relates to compounds of formula I, wherein the R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, and, in particular, their use as pharmaceuticals, for use in the treatment of urinary incontinence.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: August 17, 2010
    Assignee: Novartis AG
    Inventors: Paul William Glue, Kevin Hall McAllister, Eckhard Weber
  • Method for treating damage to gastric mucosa
    Patent number: 7776873
    Abstract: Provided is a method for treating damage to the gastric mucosa with a cytoprotective agent, comprising administering to a human in need thereof a pharmaceutical composition comprising an effective amount for treating damage to gastric mucosa of a pharmaceutically acceptable salt of revaprazan as the cytoprotective agent, and a pharmaceutically acceptable carrier. Revaprazan or its salt has an excellent treatment effect for gastrointestinal mucosal damage by potentiating a defensive factor in the gastrointestinal mucosa, simultaneously with acting as an acid pump antagonist.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: August 17, 2010
    Assignee: Yuhan Corporation
    Inventors: Ki-Baik Hahm, Dong-Kyu Kim, Mi-Sun Kwak, Sang-Aun Joo, Byoung-Seok Moon, Geun-Seog Song
  • Use of vegetable butter-based cetyl myristoleate for treating osteoarthritis and other musculoskeletal disease conditions and injuries
    Patent number: 7772279
    Abstract: A vegetable butter based dietary supplement of cetyl myristoleate is disclosed for use in the treatment of osteoarthritis and other joint inflammatory diseases of the musculoskeletal system in animals, especially equines. In its preferred form, the cetyl myristoleate is a vegetable butter-based and is administered in doses of about 4000 to about 4500 mg. The dosage may also include 3000 mg methylsulfonylmethane, 3000 mg glucosamine HCL and 1000 mg of Vitamin C.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: August 10, 2010
    Assignee: Botanoceuticals, Inc.
    Inventors: Edward C. Leonard, Dori Simonton
  • Pharmaceutical composition having prokinetic effect
    Patent number: 7767694
    Abstract: The present invention is directed to a method of treating gastrointestinal motility disorders in a subject in need thereof which includes: administering a therapeutically effective amount of O-(3-piperidino-2-hydroxypropyl) nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof, wherein the gastrointestinal motility disorders include reflux esophagitis, type II biliary and pancreatic sphincter of Oddi dysfunction, type III biliary and pancreatic sphincter of Oddi dysfunction, postcholecystectomy syndrome, non-ulcerative colitis or fecal incontinences.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: August 3, 2010
    Assignee: N-Gene Research Laboratories Inc.
    Inventors: Zoltan Szilvassy, Altila Kolonics, Kálmán Tory, Peter Literatinagy
  • Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome
    Patent number: 7749497
    Abstract: Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: July 6, 2010
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Akiko Shibata, Laurent Fischer
  • 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
    Patent number: 7737167
    Abstract: This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: June 15, 2010
    Assignee: Neurosearch A/S
    Inventors: Ulrik Svane Sørensen, Lene Teuber, Dan Peters, Dorte Strøbæk, Tina Holm Johansen, Karin Sandager Nielsen, Palle Christophersen
  • Methods of reducing weight gain associated with olanzapine treatment
    Patent number: 7737165
    Abstract: A method of reducing weight gain associated with olanzapine treatment in a human subject, by orally administering to an olanzapine-treated subject betahistine or a salt thereof, is disclosed.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: June 15, 2010
    Assignee: Mor Research Applications Ltd.
    Inventor: Nir Barak
  • Use of selective adenosine Areceptor allosteric enhancers to manipulate angiogenesis
    Patent number: 7732484
    Abstract: Disclosed is the use of selective adenosine A1 allosteric enhancers to induce angiogenesis at a desired location for treating conditions in which increased angiogenesis is desired, such as stroke, heart disease and peripheral vascular disease.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: June 8, 2010
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel Linden, Amy L. Tucker, Richard Price, Rebecca Youkey
  • Compositions for weight management
    Patent number: 7728015
    Abstract: Pharmaceutical compositions are disclosed comprising betahistine, or a salt thereof, and olanzapine in amounts effective to reduce the weight gain associated with olanzapine administration.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: June 1, 2010
    Assignee: Mor Research Applications Ltd.
    Inventor: Nir Barak
  • Use of Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting
    Patent number: 7709504
    Abstract: The present invention relates to the use of substituted 2-thio-3,5-dicyano-4-phenyl-6-amino-pyridines of the formula (I) wherein the terms A and R2 are herein defined, for treatment of nausea and vomiting.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: May 4, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Thomas Krahn, Wolfgang Thielemann, Ulrich Rosentreter, Nicole Diedrichs, Thomas Krämer
  • Method for treating sleep apnea
    Patent number: 7705039
    Abstract: A method of ameliorating a sleep-related breathing disorder via administration of at least one cannabimimetic agent, such as oleamide or ?9THC, to an individual in need of treatment.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: April 27, 2010
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David W. Carley, Miodrag Radulovacki
  • Sustained release composition for oral administration of drugs
    Patent number: 7704526
    Abstract: A sustained-release composition for oral administration of a drug, comprising the drug, a mixture of sodium alginate and xanthan gum as a carrier for sustained release and a mixture of hydroxypropyl methylcellulose and propylene glycol alginate as a gel hydration accelerator, which is capable of maintaining a constant drug level in blood for 24 hours or more. Due to rapid gel hydration without forming a non-gelated core, the drug release rate follows zero order kinetics and does not significantly vary with the degree of gastrointestinal motility.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: April 27, 2010
    Assignee: Hanmi Pharm. Co., Ltd
    Inventors: Jong-Soo Woo, Moon-Hyuk Chi
  • Methods for the treatment or inhibition of ileus
    Patent number: 7696220
    Abstract: Methods for the treatment of ileus are disclosed wherein the peripheral mu opioid antagonist methylnaltrexone is administered.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: April 13, 2010
    Assignee: Adolor Corporation
    Inventors: John J. Farrar, Peter J. Schied, William K. Schmidt, Randall L. Carpenter
  • Oral preparation of dyclonine hydrochloride
    Patent number: 7696228
    Abstract: The present invention discloses an oral preparation of dyclonine hydrochloride for the endoscopic examination in upper gastrointestinal tract, which has the effects of anesthetization and lubrication, and an oral preparation comprising dyclonine hydrochloride that has the advantages of avoiding foam in the body cavity, preventing vomiting, and offering a clear view. The preparation of the present invention comprises, as main ingredients, 0.2%-3% weight percent of dyclonine hydrochloride, 1%-12% weight percent of polyvinyl alcohol, 1%-10% volume percent of glycerin, 1%-10% volume percent of a defoaming agent, and a balance of a pharmaceutically acceptable adjuvant. The viscosity of the preparation is in a range of 30 to 300 mpa·s and the pH value is in a range of 2.0 to 8.0.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: April 13, 2010
    Assignee: Yangtze River Pharmaceutical (Group) Co., Ltd.
    Inventors: Tianjiang Sun, Xiaohong Gu, Hongguo Lu, Min Chen
  • Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof
    Patent number: 7691875
    Abstract: The present invention relates to imidazopyridine derivatives of the Formula I and, therapeutically acceptable salts thereof which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the treatment of gastrointestinal inflammatory diseases. In further aspects, the invention relates to the compound of the invention for use in therapy; to processes for preparation of such new compound; to pharmaceutical compositions containing the compound of the invention, or a therapeutically acceptable salt thereof, as active ingredient; and to the use of the compound of the invention in the manufacture of medicaments for the medical use indicated above.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: April 6, 2010
    Assignee: AstraZeneca AB
    Inventor: Peter Nordberg
  • Ultra-stable composition comprising Moringa oil and its derivatives and uses thereof
    Patent number: 7691397
    Abstract: Compositions may include long-chain organic molecules obtained from natural oils, particularly plant, bean, seed and nut oils, and their derivatives can be provided with increased oxygen stability by their combination with mixtures of particular classes of antioxidants, particularly combinations of at least one synthetic free-radical terminating antioxidant. The stabilization combination is particularly effective in combination with long-chain oils having less than 5% methylene interrupted unsaturation and free-radical terminating antioxidants present in an amount of from 0.001 to 5% or more by weight of the long-chain oils. The long-chain oil may include a natural oil or wax, such as Macadamia oil and its derivatives, Moringa oil and its derivatives, Babassu oil and its derivatives, Meadowfoam oil and its derivatives, and High Oleic Sunflower oil.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: April 6, 2010
    Assignee: International Flora Technologies, Ltd.
    Inventors: James H. Brown, Robert Kleiman
  • Treating agent for irritable bowel syndrome
    Patent number: 7683090
    Abstract: Pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: March 23, 2010
    Assignee: Astellas Pharma Inc.
    Inventors: Akito Nishida, Akira Niwa, Yutaka Atsuta